Efficacy and safety of neoadjuvant zimberelimab and cetuximab plus nab-paclitaxel and cisplatin (NeoZCPC) for resectable locally advanced hypopharyngeal/laryngeal squamous cell carcinoma: An open-label, single-arm phase II clinical trial.

Authors: Ruo-bin Lin, Fei Cao, Di Wu, Qi Fang, Zheng Zhao, Pengfei Xu, Fei Han, Xinrui Zhang, Chunyan Chen, Xuekui Liu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e18095

Source: Full article

e18095